Sudden Extramedullary and Extranodal Philadelphia-positive Anaplastic Large-Cell Lymphoma Transformation During Imatinib Treatment for CML: A Case Report

Qiong Wu,Yong Kang,Jing Xu,Wen-Can Ye,Zhen-Jiang Li,Wen-Feng He,Yuan Song,Qing-Ming Wang,Ai-Ping Tang,Ting Zhou
DOI: https://doi.org/10.12998/wjcc.v10.i28.10339
2022-01-01
World Journal of Clinical Cases
Abstract:BACKGROUND Chronic myeloid leukemia (CML) is a malignant hematologic malignancy that can progress to blast phase with a myeloid or lymphoid phenotype. Some patients with CML can also progress to blast crisis phase; however, the transformation of CML into Philadelphia-positive lymphoma is extremely rare. CASE SUMMARY We present a patient with CML who experienced a sudden transformation to anaplastic large-cell lymphoma (ALCL) after 7 mo of treatment with imatinib, during which she had achieved partial cytogenetic response as well as early molecular response. The patient noticed a mass in her left shoulder, the biopsy data of which were consistent with ALCL; moreover, her lymphoma cells exhibited BCR-ABL gene fusion. The patient was diagnosed with Philadelphia-positive ALCL that progressed from CML, and was thus treated with the second generation tyrosine kinase inhibitor nilotinib. Six months later, the mass had totally disappeared and the BCR-ABL fusion gene was undetectable in the peripheral blood. To our knowledge, this is the first patient known to have developed Philadelphia-positive ALCL transformed from CML. CONCLUSION Unexplained lymphadenopathy or an extramedullary mass in a patient with CML may warrant a biopsy and testing for BCR-ABL fusion.
What problem does this paper attempt to address?